Persistent Interleukin‐1β Elevation in Post‐COVID‐19 Patients: Findings From a Nationwide Registry Study in Japan
Neuropsychopharmacology Reports · 2026-03 · 46 (1)
DOI: 10.1002/npr2.70082 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropsychopharmacology Reports, online erschienen am 27.02.2026. Verfasst von Naoki Takamatsu und 20 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Cognitive Behavior Therapy and Research, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan. Hauptthemen laut MEDLINE: Interleukin-1beta, COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Intramural Research Grant for Neurological and Psychiatric Disorders.
Abstract (Originalsprache)
Aim
COVID‐19 has been associated with dysregulated immune responses, with increasing evidence indicating sustained inflammasome activation and subsequent pro‐inflammatory cytokine production. This study aimed to characterize the temporal profile of inflammatory markers, particularly interleukin (IL)‐1β, in post‐COVID‐19 patients compared with pre‐pandemic healthy controls, using data from the Psychiatric Symptoms for COVID‐19 Registry Japan (PSCORE‐J).
Methods
Blood samples were analyzed from 119 post‐COVID‐19 patients (median age 45 years) recruited during 2023 and 374 pre‐pandemic healthy controls (median age 65 years). For post‐COVID‐19 patients, samples were collected at baseline, 3 months, and 9 months. Multiple inflammatory markers were assessed, including IL‐1β, IL‐6, IL‐8, IL‐10, IL‐12, TNF‐α, IFN‐γ, IFN‐β, IP‐10, ACE2, and eotaxin. Age‐ and sex‐adjusted analyses were performed on log‐transformed IL‐1β levels.
Results
IL‐1β levels were significantly elevated in post‐COVID‐19 patients compared with healthy controls across all age groups (under 30s: 0.69 ± 0.33 vs. 0.25 ± 0.03; 30s: 0.70 ± 0.63 vs. 0.26 ± 0.09; 40s: 0.84 ± 0.76 vs. 0.30 ± 0.23; 50s: 0.67 ± 0.65 vs. 0.26 ± 0.10; 60 or over: 0.54 ± 0.30 vs. 0.26 ± 0.23 pg/mL). This elevation was sustained throughout the 9‐month follow‐up (baseline: 0.500 [0.33–0.890]; 3 months: 0.630 [0.28–1.290]; 9 months: 0.54 [0.29–0.96] pg/mL) compared with controls (0.24 [0.21–0.27] pg/mL). Other inflammatory markers showed either no significant differences or were paradoxically lower in patients.
Conclusion
SARS‐CoV‐2 infection is associated with persistent elevation of IL‐1β levels that remains stable over a 9‐month period, suggesting sustained inflammasome activation. These findings provide novel insight into post‐COVID‐19 inflammatory processes and may have important implications for understanding both acute and chronic manifestations of the disease. Trial Registration Japan Registry of Clinical Trials: jRCT1030220711
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Center for Cognitive Behavior Therapy and Research, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.
- Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
- Department of Clinical Data Science, Clinical Research & Education Promotion Division, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
- AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.
- Brain and Mind Research Center, Nagoya University, Nagoya, Aichi, Japan.
ORCID-Profile: Naoki Takamatsu, Hiroki Kimura, Masaki Takao, Shinsuke Kito
Förderung
- Japan Agency for Medical Research and Development
- Intramural Research Grant for Neurological and Psychiatric Disorders
Zitieren
APA
Takamatsu, N., Kimura, H., Oba, M. S., Chiba, H., Umemoto, I., Moriyama, Y., Matsunaga, N., Morioka, S., Mori, D., Hara, K., Ogura, A., Yoshida, K., Watanabe, H., Maesawa, S., Ikeda, M., Katsuno, M., Ohmagari, N., Takao, M., Kito, S., …, & Kuga, H. (2026). Persistent Interleukin‐1β Elevation in Post‐COVID‐19 Patients: Findings From a Nationwide Registry Study in Japan. Neuropsychopharmacology Reports, 46(1). https://doi.org/10.1002/npr2.70082
Vancouver
Takamatsu N, Kimura H, Oba MS, Chiba H, Umemoto I, Moriyama Y, et al. Persistent Interleukin‐1β Elevation in Post‐COVID‐19 Patients: Findings From a Nationwide Registry Study in Japan. Neuropsychopharmacology Reports. 2026;46(1). doi:10.1002/npr2.70082
BibTeX
@article{Takamatsu2026,
author = {Takamatsu, Naoki and Kimura, Hiroki and Oba, Mari S and Chiba, Hiroyuki and Umemoto, Ikue and Moriyama, Yuki and Matsunaga, Nobuaki and Morioka, Shinichiro and Mori, Daisuke and Hara, Kazuhiro and Ogura, Aya and Yoshida, Kazufumi and Watanabe, Hirohisa and Maesawa, Satoshi and Ikeda, Masashi and Katsuno, Masahisa and Ohmagari, Norio and Takao, Masaki and Kito, Shinsuke and Ozaki, Norio and Kuga, Hironori},
title = {Persistent Interleukin‐1β Elevation in Post‐COVID‐19 Patients: Findings From a Nationwide Registry Study in Japan},
journal = {Neuropsychopharmacology Reports},
year = {2026},
volume = {46},
number = {1},
doi = {10.1002/npr2.70082}
}
EUVIMED